Local Drug Delivery for Coronary Artery Disease: Established and Emerging Applications

ISBN-13: 9781841840451 / Angielski / Twarda / 2005 / 608 str.

Edoardo Camenzind; Ivan K. De Scheerder

Opis

The two greatest problems associated with PTCA are abrupt or threatened vessel closure and restenosis, stents were initially thought to be the remedy. Unfortunately, this has not proven so: the material of which the stent is composed, along with stent-induced vascular injury, has led to thrombotic effects. Numerous pharmacological agents have been tested in order to reduce acute thrombosis and the hyperproliferative cellular response. Many of these work. Given that stents are used frequently in the catheter lab, it is no surprise that stents are being used for local drug delivery. Pioneers in the field, Camenzind and De Scheerder have assembled an excellent team of contributors to offer their experience of local drug delivery to the reader.

Spis treści

GENERAL INTRODUCTION
Introduction
Purposes of the Site-specific Therapy: Arterial Wall Passivation
Local Drug Delivery: Impact of Pressure, Substance Characteristics and Stenting on Drug Transfer Into the Arterial Wall

SYLLABUS OF THE PLATFORMS FOR LOCAL VASCULAR DRUG DELIVERY
Catheter-based and Stent-based Treatment for Coronary Artery Disease
The ClearWay™ Microporous Balloon Catheter
DISPATCH® Coronary Infusion Catheter
REMEDY™ PTCA Dilation Infusion Catheter
Infiltrator angioplasty Balloon Catheter
The Infiltrator™ Local Drug Delivery Catheter
The Needle Catheter
Stent Mediated Local Drug Delivery

INERT AND NON-ELUTING COATINGS
Silicon Carbide-coated Stents
Carbostent: A Carbofilm™ Coated Stent
The PC-coated BiodivYsio™ Stent
PTFE Covered Stent

DRUG ELUTING COATINGS
Overview about Drug Delivery Coatings
Phosphorylocholine (PC Technology™) Coated stents as a Drug Delivery Platform
Direct Stent Coating: An Alternative for Polymers?
Radioactive Stents

SYLLABUS OF THERAPEUTIC AGENTS
Overview of Potential Interesting Drugs to Inhibit in-stent Restenosis
Direct Antithrombins
Tissue Factor Inhibitors
Nitric Oxide Related Interventions and Restenosis
Vitamin E and its Multiple Properties: Anti, Pro, and Non-oxidative Activities
Dexamethasone Eluting Stent
Anti-inflammatory Approaches to Restenosis
The Role of Matrix Metalloproteinases Inhibitors after Arterial Injury
Methotrexate: A Potential Interesting Drug for Stent Mediated Local Drug Delivery anti-inflammatory and anti Proliferative Characteristics
Actin-skeleton Inhibitors: Poetential Candidates for Local Drug Delivery in the Prevention of an In-stent Restenosis?
Local Delivery of Antisense Oligomers to c-myc for the Prevention of Restenosis

PRE-CLINICAL STUDIES
Character-based Intravascular Delivery
Stent-based Intravascular Delivery

CLINICAL STUDIES
Catheter-based Local Heparin Delivery
Local Delivery of Low Molecular Weight Heparins
Local Delivery of Steroids before Coronary Stent Implantation
Clinical Studies with the Carbostent
Gold Coated Stents
Heparin-coated Stent trials
The Blue Medical 50% TEMPO Coronary Stent: Pre-clinical Study and the First In-man Pilot Trial
Dexamethasone: Mode of action, Pre-clinical and Clinical Studies
ß-edstradiol Eluting Stents - A Potential Therapy in the Prevention of Restenosis
Batimastat: Mode of Action, Preclinical and Clinical Studies
FIM Trial
Tacrolimus Eluting Stents
Everolimus Eluting Stents
Endeavor Drug-eluting Stent Systems
The Quanam Drug-eluting Stent and the SCORE Trial
The Boston Scientific Paclitaxel-eluting Stent: TAXUS I and II
Clinical Results with Non-polymer Based Taxol-eluting Stents: The European EvaLUation of pacliTaxel Eluting Stent (ELUTES) Trial

ALTERNATIVE METHODS FOR LOCAL VCASCULAR DRUG DELIVERY
Intrapericardial Drug Delivery for Prevention of Restenosis
Alternatives to Drug-eluting Stents: Safety and Efficacy of Systemic Delivery of Anti-proliferative Therapy to Reduce In-stent Neointimal Hyperplasia

LOCAL DRUG DELIVERY: A CRITICAL PERSPECTIVE
Drug-eluting Stents: A Critical Perspective

O autorze

Edoardo Camenzind and Ivan K De Scheerder